Yükleniyor... / Loading...
This Phase 1 study evaluates the effect of the experimental drug PF-04427429 on the capsaicin-induced skin flare response, compared with placebo and EMLA, in healthy volunteers. It included healthy male volunteers aged 18-50. It was carried out in Phase 1 and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Healthy male subjects between the ages of 18 and 50 years inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests. * Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the trial. * Skintype I-III with a distance from base of scaphoid to antecubital fossa \>26cm on their forearms. Exclusion Criteria: * Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, genitourinary, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, symptomatic, seasonal allergies at time of dosing). * Use of biologics including any live vaccines within 3 months prior to screening or prior treatment with an antibody in a previous clinical trial or treatment with an immunoglobulin in the past 6 months. * 12-lead ECG demonstrating QTcF \>450 msec at screening. * Subjects with scars or tattoos on the forearms, or with evidence of sunburn, or excessive hairy volar forearms.